SREBF1 and glioblastoma: EGFR-activating mutation (EGFRvIII) can promote SREBP-1 cleavage and cause a higher expression of nuclear SREBP-1 to elevate LDLR expression in GBM patient samples, tumors cells, and mouse models, which is dependent on the PI3K/Akt pathway (15, 87).